Why Is Oxford Nanopore Technologies Up Today?
Oxford Nanopore Technologies PLC shares rose 2.15% today to around 175.90p, as investors respond positively to the DNA and RNA sequencing specialist's progress in expanding beyond its core research customer base into higher-value clinical and biopharma applications.
The move continues a volatile but broadly improving run for the stock since the appointment of new chief executive Francis Van Parys, with the company sharpening its strategic focus around four key priorities designed to accelerate the path to profitability.
Key Highlights
Oxford Nanopore reported preliminary 2025 Revenue of £223–224 million, up as much as 22% on a reported basis and 24% at constant currency, slightly ahead of prior guidance. Clinical revenue grew 60% and biopharma revenue grew 30% on a reported basis, with applied markets now representing around a third of total revenue.
For H1 2026, revenue reached approximately £116.7 million, up around 11% year-on-year, though this came in below internal expectations due to weakness in China and the Middle East. The company has set a target of exceeding $700 million in annual revenue by 2030, alongside a goal of reaching adjusted EBITDA break-even in 2027.
About Oxford Nanopore Technologies
Oxford Nanopore develops nanopore-based sequencing technology that enables real-time analysis of DNA and RNA molecules, with applications spanning life-science research, clinical diagnostics, biopharma development, industrial and agricultural testing. Its flagship products include the portable MinION and high-throughput PromethION platforms.
The company differentiates itself through native, direct sequencing of DNA and RNA without amplification, allowing detection of modifications such as methylation alongside sequence data — a capability increasingly valued in complex clinical and biopharma applications.
Key Reasons Behind Today's Rally
Today's gain reflects continued optimism that Oxford Nanopore's strategic reset — announced under new Leadership — can accelerate profitable growth. The company has outlined four priorities: focusing on high-value applications in biopharma, clinical and research markets; improving scalability of its products and workflows; simplifying its product portfolio; and improving workforce efficiency.
Recent commercial progress, including a cross-licensing deal reported to be worth around $20 million and a Partnership with MyOme to embed Oxford Nanopore's sequencing technology into a rare disease test commercialised by Natera, has reinforced confidence in the company's ability to convert its technology into recurring, higher-margin applied revenue.
Applied Markets Are Now the Key Growth Driver
Management believes applied markets — clinical, biopharma and industrial — will overtake life-science research as Oxford Nanopore's largest revenue stream by 2030. In H1 2026, clinical revenue grew 15% of total revenue, up from 13% a year earlier, while biopharma also expanded its share, even as the group navigated a slowdown in China linked to export controls.
The company continues to push platform improvements, including throughput gains on PromethION, the launch of the MK1D device, and accuracy improvements aimed at eventually enabling low-cost, high-accuracy genome sequencing — technology developments management believes will widen Oxford Nanopore's addressable market over time.
Path to Profitability
A shift toward a capital-expenditure-light commercial model has improved Cash Flow by around £20 million and boosted gross Margin by more than 500 basis points, supporting management's goal of reaching EBITDA break-even in 2027. The company held just over £300 million in cash as of early 2026, providing a runway to execute its strategy without near-term financing risk.
For full-year 2026, Oxford Nanopore has guided to constant-currency revenue growth of 21–25%, although management noted that, excluding one-off licensing and collaboration revenue, underlying growth is now expected closer to 16–20%, reflecting continued softness in China, disruption in the Middle East and order timing in the Americas.
Risks
Oxford Nanopore remains loss-making, and continued execution risk exists around converting applied-market opportunities into durable revenue at attractive margins. Enhanced export controls affecting China have already weighed on recent results and could persist or intensify.
Disruption linked to conflicts in the Middle East and order timing Volatility in the Americas add further near-term uncertainty to revenue trajectories, while competition from established players in genomics and sequencing continues to intensify.
The recent leadership transition, with a new CEO implementing a strategic reset, carries its own execution risk as priorities are re-ordered and portfolio simplification is carried out.
Valuation
Oxford Nanopore trades as a growth and innovation story rather than on current profitability, given the company remains loss-making. The valuation reflects investor expectations around the size of the applied-markets opportunity and the credibility of the 2027 EBITDA break-even and $700 million 2030 revenue targets.
Any evidence that the applied-markets pivot is delivering durable margin improvement, alongside stabilisation in China and the Middle East, could support a re-rating; conversely, further guidance downgrades would likely weigh on sentiment given the stock's growth-dependent valuation.
What Investors Should Watch Next
Key metrics include the split of revenue between research and applied markets, progress toward EBITDA break-even, the pace of recovery (or further deterioration) in China, and additional commercial partnerships in clinical and biopharma applications.
Updates on platform performance, including PromethION throughput and accuracy improvements, will also be important in assessing Oxford Nanopore's long-term competitive position.
Conclusion
Oxford Nanopore's 2.15% gain today reflects cautious optimism that the company's strategic reset toward higher-value applied markets, combined with continued platform innovation, can put it on a credible path to profitability.
While near-term headwinds in China and the Middle East have muddied the growth picture, the long-term opportunity in clinical, biopharma and industrial sequencing remains substantial, and execution against the 2027 and 2030 targets will be the key determinant of Shareholder returns from here.






Please wait processing your request...